10/05/2026
📚 New research highlights an important reality of modern weight-loss medications.
An article in The Journal of Clinical Endocrinology & Metabolism explores what happens when incretin-based weight-loss medications (such as GLP-1 therapies) are discontinued.
While these medications can lead to significant weight loss (around 5–24%) and improvements in cardiometabolic health, many patients stop treatment within 1–2 years due to factors like side effects, cost, access issues, or limited response.
The challenge?
Stopping treatment often leads to weight regain and reversal of health benefits, creating difficulties in maintaining long-term progress.
The paper highlights real-world patient cases and emphasises the importance of ongoing strategies to maintain weight loss, including:
✔️ Structured lifestyle support
✔️ Long-term medical follow-up
✔️ Alternative treatment pathways when medications are stopped
At our clinic, we take a long-term, comprehensive approach to obesity treatment. For some patients, metabolic and bariatric surgery may provide a more durable option for achieving and maintaining significant weight loss and improving obesity-related health conditions.
If you’re exploring options for managing weight and improving your long-term health, our team is here to help guide you through evidence-based treatment pathways.
Read more here: https://academic.oup.com/jcem/article-abstract/111/3/870/8355048